News Image

Is NYSE:PFE a Good Fit for Dividend Investing?

By Mill Chart

Last update: Nov 2, 2023

Unearth the potential of PFIZER INC (NYSE:PFE) as a dividend stock recommended by our stock screening tool. NYSE:PFE maintains a robust financial footing and delivers a sustainable dividend. We'll delve into the details below.

Assessing Dividend Metrics for NYSE:PFE

ChartMill assigns a proprietary Dividend Rating to each stock. The score is computed by evaluating various valuation aspects, like the yield, the history, the dividend growth and sustainability. NYSE:PFE was assigned a score of 8 for dividend:

  • PFE has a Yearly Dividend Yield of 5.37%, which is a nice return.
  • Compared to an average industry Dividend Yield of 4.50, PFE pays a better dividend. On top of this PFE pays more dividend than 97.57% of the companies listed in the same industry.
  • PFE's Dividend Yield is rather good when compared to the S&P500 average which is at 2.78.
  • PFE has been paying a dividend for at least 10 years, so it has a reliable track record.
  • PFE has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.

Assessing Health for NYSE:PFE

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NYSE:PFE has received a 5 out of 10:

  • With a decent Altman-Z score value of 2.60, PFE is doing good in the industry, outperforming 72.33% of the companies in the same industry.
  • PFE has a Debt to FCF ratio of 6.13. This is amongst the best in the industry. PFE outperforms 84.47% of its industry peers.
  • PFE has a Current Ratio of 2.12. This indicates that PFE is financially healthy and has no problem in meeting its short term obligations.

Profitability Examination for NYSE:PFE

ChartMill assigns a proprietary Profitability Rating to each stock. The score is computed by evaluating various profitability ratios and margins and ranges from 0 to 10. NYSE:PFE was assigned a score of 8 for profitability:

  • The Return On Assets of PFE (9.75%) is better than 90.78% of its industry peers.
  • With an excellent Return On Equity value of 21.68%, PFE belongs to the best of the industry, outperforming 91.26% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 11.96%, PFE belongs to the best of the industry, outperforming 89.81% of the companies in the same industry.
  • The last Return On Invested Capital (11.96%) for PFE is well below the 3 year average (16.16%), which needs to be investigated, but indicates that PFE had better years and this may not be a problem.
  • PFE's Profit Margin of 27.55% is amongst the best of the industry. PFE outperforms 94.66% of its industry peers.
  • The Operating Margin of PFE (31.21%) is better than 95.63% of its industry peers.
  • In the last couple of years the Operating Margin of PFE has grown nicely.
  • Looking at the Gross Margin, with a value of 68.78%, PFE is in the better half of the industry, outperforming 74.76% of the companies in the same industry.

Every day, new Best Dividend stocks can be found on ChartMill in our Best Dividend screener.

Our latest full fundamental report of PFE contains the most current fundamental analsysis.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

PFIZER INC

NYSE:PFE (4/26/2024, 7:09:35 PM)

Premarket: 25.5 +0.1 (+0.39%)

25.4

+0.14 (+0.55%)

PFE News

News Imagean hour ago - Pfizer Inc.Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting
News Image2 hours ago - InvestorPlace3 Dividend Stocks to Buy on the Dip: April 2024

With the market presenting many vagaries, investors may take some solace in these dividend stocks to buy on the dip.

News Image14 hours ago - The Business JournalsPfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose

Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.

News Image22 hours ago - The Motley FoolIs Viking Therapeutics Incredibly Undervalued?

The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.

News Imagea day ago - The Motley Fool3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street

Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.

News Image2 days ago - The Motley Fool3 Dividend Stocks to Buy and Hold for the Next Decade

You'll get dividends and more with these great stocks.

News Image2 days ago - InvestorPlace7 Dividend Stocks to Buy Now for Steady Returns in Any Market

Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.

News Image3 days ago - CNBCCramer's week ahead: Fed meeting and earnings from Apple, Amazon, Eli Lilly

CNBC's Jim Cramer on Friday walked investors through next week on Wall Street.

News Image3 days ago - Market News VideoJune 7th Options Now Available For Pfizer (PFE)
News Image3 days ago - The Motley FoolWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks

Put your money to work by investing in these three high-quality dividend stocks.

News Image3 days ago - BloombergPfizer’s First Gene Therapy Gets Approval for Clotting Disorder

Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.

News Image3 days ago - CNBCFDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder

The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B. 

PFE Links
Follow us for more